title: Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction.
authors.forename: Daniela
authors.initials: D
authors.lastname: Francisci
authors.forename: Emanuela
authors.initials: E
authors.lastname: Falcinelli
authors.forename: Barbara
authors.initials: B
authors.lastname: Belfiori
authors.forename: Eleonora
authors.initials: E
authors.lastname: Petito
authors.forename: Tiziana
authors.initials: T
authors.lastname: Fierro
authors.forename: Franco
authors.initials: F
authors.lastname: Baldelli
authors.forename: Paolo
authors.initials: P
authors.lastname: Gresele
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016022:Case-Control Studies; D018932:Chemokine CCL2 / Q000187:drug effects / Q000378:metabolism; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000503:physiopathology* / Q000821:virology; D015497:HIV-1; D006801:Humans; D008875:Middle Aged; D063065:Organophosphonates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000068698:Tenofovir; D019010:Vascular Cell Adhesion Molecule-1 / Q000187:drug effects / Q000378:metabolism; D014664:Vasodilation / Q000187:drug effects; D000099227:Abacavir
chemical_list: D000225:Adenine; D019380:Anti-HIV Agents; D018932:Chemokine CCL2; D015224:Dideoxynucleosides; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D019010:Vascular Cell Adhesion Molecule-1; D000099227:Abacavir; C111835:CCL2 protein, human